Physician profile
Priti Sud
NPI 1275673915
$3,362.18
in general payments reported to CMS, 2019-2025
27 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $141 · 2021: $98.87 · 2022: $212 · 2023: $541 · 2024: $760 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,741 · Education: $34.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,741.05 |
| Education | $34.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,114.00 | 2019-2025 | Linzess, Viberzi, Skyrizi |
| Janssen Biotech, INC. | $495.62 | 2024-2025 | Tremfya, Stelara |
| Ipsen Biopharmaceuticals, INC | $190.50 | 2024-2025 | Iqirvo |
| Echosens North America, INC. | $185.40 | 2023 | Fibroscan |
| Pfizer INC. | $174.60 | 2023-2025 | |
| Lilly USA, LLC | $167.58 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $149.20 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $127.27 | 2024-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $86.68 | 2025 | |
| Braintree Laboratories, INC. | $83.13 | 2023-2025 | Suflave, Sutab |
| Madrigal Pharmaceuticals | $78.68 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $73.43 | 2024-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $51.17 | 2019-2024 | |
| Shionogi INC | $50.59 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.61 | 2020-2025 | Xifaxan |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $39.25 | 2023-2024 | Rebyota, Cimzia |
| Qol Medical, LLC | $34.82 | 2025 | Sucraid |
| Ardelyx, INC. | $32.66 | 2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $31.40 | 2025 | Dupixent |
| Evoke Pharma, INC. | $30.26 | 2024-2025 | |
| Celltrion USA INC. | $29.90 | 2025 | Vegzelma |
| Gilead Sciences, INC. | $19.70 | 2019 | |
| Intra-Sana Laboratories | $19.31 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Exact Sciences Corporation | $18.72 | 2025 | Cologuard Collection Kit |
| Medtronic, INC. | $13.77 | 2021 | |
| Companion Medical, INC. | $13.64 | 2020 | |
| Allergan, INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priti Sud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.